Endometriosis Treatment Market Size in the 7MM was USD 2,300 million in 2023 and is expected to grow significantly by 2034, estimates DelveInsight

DelveInsight's "Endometriosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore Endometriosis Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Endometriosis Market Report
• In December 2025, Gesynta Pharma AB conducted a Phase 2 clinical trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial
• The Endometriosis market size was valued ~USD 2,300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• Among the total endometriosis market size across the 7MM, the United States held the largest share, reaching approximately USD 1,400 million in 2023.
• In 2023, the UK held the largest market share at approximately 20% within the EU4 and UK region, while Spain had the smallest share.
• In 2023, there were approximately 10.8 million diagnosed prevalent cases of endometriosis across the 7MM, with the highest number reported in the United States.
• Endometriosis is most prevalent among females aged 18-29, accounting for approximately 40% of all cases in the 7MM.
• In 2023, the total number of treated endometriosis cases was approximately 2.9 million in the US, followed by the UK and France.
• As per the findings of Yoshino et al. (2022), around 2.6 million women in Japan are impacted by endometriosis.
• The leading Endometriosis Companies such as AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others
• Promising Endometriosis Therapies such as ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 μg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others

Strategize your business goals by understanding market dynamics @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Overview
Endometriosis is a chronic condition in which tissue similar to the lining of the uterus (endometrium) grows outside the uterus, commonly on the ovaries, fallopian tubes, or pelvic lining. This misplaced tissue behaves like normal endometrial tissue-thickening, breaking down, and bleeding with each menstrual cycle-but has no way to exit the body, leading to inflammation, pain, and scar tissue formation. Symptoms often include pelvic pain, painful periods, infertility, and digestive issues. While there is no cure, treatment options such as hormonal therapy, pain relievers, and surgery can help manage symptoms and improve quality of life.

Endometriosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endometriosis Epidemiology Segmentation:
The Endometriosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Endometriosis
• Prevalent Cases of Endometriosis by severity
• Gender-specific Prevalence of Endometriosis
• Diagnosed Cases of Episodic and Chronic Endometriosis

Visit for more about Endometriosis Prevalence @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometriosis market or expected to get launched during the study period. The analysis covers Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Endometriosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Endometriosis Therapies and Key Companies
• ORILISSA (elagolix): AbbVie
• MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceutical
• Leuprolide Oral Tablet: Enteris BioPharma Inc.
• SN132D: Spago Nanomedical AB
• OG-6219: Iqvia Pty Ltd
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• Relugolix: Myovant Sciences GmbH
• HMI-115: Hope Medicine (Nanjing) Co., Ltd
• Quinagolide 1080 μg: Ferring Pharmaceuticals
• OBE2109: ObsEva
• SASHR7280: Jiangsu HengRui Medicine
• Estradiol/Norethindrone Acetate: AbbVie
• TAK-385: ASKA Pharmaceutical Co., Ltd.
• NBI-56418 (GnRH antagonist): Abbott
• KLH-2109: Kissei Pharmaceutical Co., Ltd.
• Dienogest (Visanne, BAY86-5258): Bayer
• ERB-041: Pfizer

For more information, visit Endometriosis Medication and Companies @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Market Strengths
• The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms
• At national and international levels, government and key market players actively invest in research and development and increase funds, further catering to market growth.

Endometriosis Market Opportunities
• Incumbents are paired with healthcare providers to raise awareness in the field of endometriosis at the physician and patient levels
• New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool

Scope of the Endometriosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Endometriosis Companies: AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others
• Key Endometriosis Therapies: ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109) , Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 μg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Endometriosis Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement

Do you know the treatment paradigms for different countries? Download our Endometriosis Treatment Market @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Endometriosis Market Report Introduction
2. Executive Summary for Endometriosis
3. SWOT analysis of Endometriosis
4. Endometriosis Patient Share (%) Overview at a Glance
5. Endometriosis Market Overview at a Glance
6. Endometriosis Disease Background and Overview
7. Endometriosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Endometriosis
9. Endometriosis Current Treatment and Medical Practices
10. Endometriosis Unmet Needs
11. Endometriosis Emerging Therapies
12. Endometriosis Market Outlook
13. Country-Wise Endometriosis Market Analysis (2020-2034)
14. Endometriosis Market Access and Reimbursement of Therapies
15. Endometriosis Market Drivers
16. Endometriosis Market Barriers
17. Endometriosis Appendix
18. Endometriosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.